Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate cyclase type 10 (ADCY10) encodes a soluble adenylyl cyclase, a cytoplasmic enzyme responsible for catalyzing the conversion of ATP to cyclic AMP (cAMP), a ubiquitous second messenger involved in intracellular signaling. Unlike transmembrane adenylyl cyclases, ADCY10 is regulated by intracellular bicarbonate and is not controlled by G protein or forskolin. It plays critical roles in sperm function (including maturation, motility, and capacitation), pH regulation in renal and epididymal tissues, ciliary movement, and localized cAMP signaling within various cellular compartments (cytosol, nucleus, mitochondria). Mutations in ADCY10 are associated with male infertility and absorptive hypercalciuria. There are currently no approved therapeutic agents targeting ADCY10, but research continues into its physiological relevance and potential as a drug target.
Not applicable for clinical drugs; for research inhibitors, mechanism is typically competitive inhibition of the catalytic domain, preventing cAMP formation from ATP
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylate cyclase type 10 (ADCY10).